Patents by Inventor Glenn Nedwin

Glenn Nedwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6406679
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds &bgr;-galactoside-containing moieties independent of the presence or absence of Ca+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: June 18, 2002
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhamer, Glenn Nedwin, Tim Bringman, Pierre-Oliver Couraud
  • Patent number: 6245334
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds &bgr;-galactoside-containing moieties independent of the presence or absence of Ca+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 12, 2001
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhammer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
  • Patent number: 6153195
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: November 28, 2000
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhammer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
  • Patent number: 5710257
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: January 20, 1998
    Inventors: Jeffrey J. Seilhamer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
  • Patent number: 5693760
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: December 2, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhammer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
  • Patent number: 5633148
    Abstract: A human HL-60 lectin having an amino acid sequence different from other known animal lectins is disclosed. This is one member of a class of mammalian lectins extractable in lactose or detergent and specific for beta-D-galactosides (14-beta-gal lectin which contains at least one glycosylation site). Recombinant methods and materials for production of the mammalian 14-beta-gal lectins, especially HL-60 lectin, in a variety of hosts, and methods to utilize the resulting lectins are also described.
    Type: Grant
    Filed: December 6, 1995
    Date of Patent: May 27, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud